Alzheon Inc. has published updated analyses from two failed 2007 Phase III studies for Alzheimer's therapy tramiprosate, providing details it hopes will help guide an improved version of the compound, ALZ-801, through pivotal late-stage trials and sequential regulatory filings. However, this new subgroup analysis has raised concerns and highlighted possible pitfalls for future studies of Alzheon's up-cycled therapy.
Tramiprosate's ill-fated Phase III program included two similarly designed, 78-week trials in patients with mild-to-moderate Alzheimer's disease
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?